Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
- 1 May 2018
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (5), 725-734
- https://doi.org/10.1001/jamaoncol.2017.5305
Abstract
Importance The incidence of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adolescent and young adult (AYA) patients (age range, 15-39 years) in the United States is increasing at a greater rate than in younger or older persons. Their optimal treatment has been increasingly debated as pediatric regimens have become more widely used in the age group. This review compares the basic features of pediatric and adult chemotherapy regimens for ALL and LBL, recognizes and describes the challenges of the pediatric regimen, and suggests strategies to facilitate its adoption for AYAs with ALL and LBL. Observations All but 2 of 25 published comparisons of outcomes with pediatric and adult regimens for ALL and LBL in AYAs and 1 meta-analysis favor the pediatric regimen. After more than a half-century of clinical trials of the pediatric regimens, including at least 160 phase 3 trials in the United States, the pediatric regimens have become far more complex than most adult regimens. Asparaginase, a critical component of the pediatric regimens, is more difficult to administer to AYAs (and older patients) but nonetheless has a favorable benefit to toxicity ratio for AYAs. A dramatic reduction in outcome of ALL and LBL during the AYA years (the “survival cliff”) is coincident with similar reductions in proportions of AYAs referred to academic centers and enrolled on clinical trials (the “accrual cliff” and “referral cliff”). Conclusions and Relevance The accumulating data increasingly support treating AYAs with ALL and LBL with a pediatric-inspired regimen or an approved institutional or national clinical trial tailored for this patient group. A need to develop clinical trials specifically for AYAs and to encourage their participation is paramount, with a goal to improve both the quantity and quality of survival.Keywords
This publication has 61 references indexed in Scilit:
- Differential survival improvement for patients 20–29 years of age with acute lymphoblastic leukemiaLeukemia Research, 2013
- Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysisBlood, 2013
- Children, Adolescents, and Young Adults With Leukemia: The Empty Half of the Glass Is GrowingJournal of Clinical Oncology, 2012
- Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panelLeukemia & Lymphoma, 2011
- Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2009
- What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesBlood, 2008
- Acute lymphoblastic leukemia in adolescents and young adults in FinlandHaematologica, 2008
- Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511Blood, 2007
- Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in SwedenCancer, 2006
- Adolescents and young adults with cancerCancer, 2006